Fluid status established by bioimpedance vector analysis (BIVA) at diagnosis of wild-type transthyretin amyloidosis is associated with patient survival

Back

ESC2025 Premium Access

Fluid status established by bioimpedance vector analysis (BIVA) at diagnosis of wild-type transthyretin amyloidosis is associated with patient survival

Session: Improving treatment of transthyretin cardiac amyloidosis

Topic: Infiltrative Myocardial Disease

Speaker: Doctor J. Mansell (London, GB)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Josephine Mansell

National Amyloidosis Centre, London (United Kingdom of Great Britain & Northern Ireland)

1 follower

4 more presentations in this session

Assessing functional capacity in patients with ATTR-CM: the role of CPET and 6MWT

Speaker: Doctor A. Sheikh (London, GB)

Addressing unmet needs in ATTR-CM management: insights from EU4 cardiologists

Speaker: Mr P. Collins (London, GB)

Novel self-supervised learning outperforms traditional AI in ECG-based transthyretin cardiac amyloidosis detection for earlier diagnosis

Speaker: Mr D. Mcauliffe (Dublin, IE)

Impact of Tafamidis on survival in elderly patients in a real-world setting: insights from the Healthcare European Amyloidosis Registry

Speaker: Doctor A. Jobbe Duval (Villeurbanne, FR)

Access the full session

Improving treatment of transthyretin cardiac amyloidosis

Speakers: Doctor J. Mansell, Doctor A. Sheikh, Mr P. Collins, Mr D. Mcauliffe, Doctor A. Jobbe Duval

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources